On January 8, Johnson & Johnson announced that it had reached an agreement with the Trump administration to lower drug prices in the United States in exchange for U.S. tariff exemptions. Johnson & Johnson has become another pharmaceutical company, following GlaxoSmithKline, Merck, and Novartis, to reach a drug price reduction agreement with the new U.S. administration.

President Trump previously sent letters to 17 pharmaceutical companies, urging them, including Johnson & Johnson, to significantly reduce drug prices.

Pfizer and AstraZeneca acted swiftly, being the first to reach agreements with the government, agreeing to lower prescription drug prices in exchange for tariff reductions, setting a precedent for subsequent pharmaceutical negotiations.

Eli Lilly and Novo Nordisk have also reached relevant agreements. They have significantly lowered the prices of commonly used GLP-1 weight-loss drugs for Medicare, Medicaid, and self-paying patients in the United States.